Common Genetic Variants in the MicroRNA Biogenesis Pathway Are not Associated with Breast Cancer Risk in Asian Women

Hyuna Sung1, Ben Zhang2, Ji-Yeob Choi1,4, Jirong Long6, Sue K. Park1,2,4, Keun-Young Yoo2, Dong-Young Noh1,4, Sei-Hyun Ahn5, Wei Zheng6, and Daehee Kang1,2,4

Abstract

Background: Although the role of miRNA in cancer development and progression has been well established, the association between genetic variants in miRNA biogenesis pathway genes and breast cancer risk has been yet unclear.

Methods: We analyzed data from two genome-wide association studies conducted in East Asian women including 5,066 cases and 4,337 controls. Among the single-nucleotide polymorphisms (SNP), which were directly genotyped or imputed, we selected 237 SNPs in 32 genes involved in miRNA biogenesis pathway and its regulation.

Results: Although eight SNPs were nominally associated with breast cancer risk in combined samples (P < 0.05), none of them were significant after adjustment for multiple comparisons.

Conclusions: The common genetic variants in miRNA biogenesis pathway genes may not be associated with breast cancer risk.

Impact: This study suggests no association between the polymorphisms in miRNA biogenesis pathway genes and breast cancer risk. Studies with large sample size and more genetic variants should be warranted to adequately evaluate the potential association. Cancer Epidemiol Biomarkers Prev; 1–3. ©2012 AACR.

Introduction

miRNAs are a major class of noncoding RNAs that posttranscriptionally modulate gene expression in a sequence specific manner. The role of miRNAs in human cancer pathogenesis has been well established by the identification of aberrant expression of miRNAs in many types of cancer (1). There is increasing evidence that the genetic variants in miRNA genes, in their biogenesis pathway genes and binding sites of target mRNA are associated with cancer risk and survival (2). However, the association between the polymorphisms of miRNA biogenesis pathway genes and breast cancer risk is uncertain. The previous study focusing on this pathway was conducted in small sample size and the coverage of genes of interests was limited (3). More recently, the results on the effects of genetic variants in miRNA biogenesis pathway genes were inconsistent even in the same cancer type (4). We comprehensively evaluated the common variants in miRNA biogenesis pathway genes by analyzing data from the 2 previous genome-wide association studies (GWAS) conducted in women of Asian ancestry consisted of 5,066 breast cancer cases and 4,337 controls.

Materials and Methods

Detailed methods for the Seoul Breast Cancer Study and the Shanghai Breast Cancer Study have been published elsewhere (5, 6) and described in brief in Supplementary Table S1 (3). This study included 5,066 histologically confirmed breast cancer cases and 4,337 controls [(2,190/2,052) Koreans and (2,876/2,285) Chinese]. The protocol was approved by the Institutional Review Board, and all participants provided written informed consent.

The 35 genes (ADAR, ADARB1, DDX5, DDX17, DDX20, DICER1, DROSHA, EIF2C1, EIF2C2, GEMIN4, HNRNPA1, IFL2, IFL3, KHSRP, LIN28A, NANOG, PAPD4, PIWIL1, RAN, SMAD1, SMAD2, SMAD3, SMAD4, SMAD6, SMAD7, SNIP1, SRRT, SRSF1, TARB1, TRIM32, TRIM71, XPO5, XRN2, and ZCCHC11) were selected on the basis of their biologic role in miRNA biogenesis as determined by the combination of literature review (7) and the bioinformatics tool the Gene Ontology...
Table 1. Association between the SNPs with a $P_{meta} < 0.050$ in the genes of interest and breast cancer risk

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genomic location</th>
<th>Allele</th>
<th>Genotype</th>
<th>EAF$^c$</th>
<th>Per-allele OR (95% CI)</th>
<th>$P_{meta}$</th>
<th>$R^2$</th>
<th>$P_{adj}$</th>
<th>$P_{Q}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDX20</td>
<td>1p13.2/112104760</td>
<td>A/T</td>
<td>0.10</td>
<td>0.94 (0.81–1.08)</td>
<td>1.00</td>
<td>0.37</td>
<td>0.86 (0.74–1.00)</td>
<td>0.05</td>
<td>0.45</td>
</tr>
<tr>
<td>EIF2C2</td>
<td>8q24.3/141693661</td>
<td>C/T</td>
<td>0.08</td>
<td>1.29 (1.08–1.54)</td>
<td>0.80</td>
<td>0.01</td>
<td>0.96 (0.91–1.29)</td>
<td>0.02</td>
<td>0.10</td>
</tr>
<tr>
<td>PIWIL1</td>
<td>12q24.33/129405118</td>
<td>A/G</td>
<td>0.09</td>
<td>0.82 (0.70–0.96)</td>
<td>0.91</td>
<td>0.01</td>
<td>0.96 (0.84–0.99)</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>DICER1</td>
<td>14q32.13/94674881</td>
<td>A/G</td>
<td>0.30</td>
<td>0.94 (0.83–0.98)</td>
<td>0.02</td>
<td>0.51</td>
<td>0.98 (0.97–1.00)</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>SMAD6</td>
<td>15q22.31/64784141</td>
<td>A/G</td>
<td>0.83</td>
<td>1.12 (0.99–1.26)</td>
<td>0.89</td>
<td>0.08</td>
<td>1.09 (0.97–1.21)</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>SMAD6</td>
<td>15q22.31/64843093</td>
<td>A/G</td>
<td>0.06</td>
<td>0.77 (0.64–0.93)</td>
<td>0.99</td>
<td>0.01</td>
<td>0.98 (0.82–1.16)</td>
<td>0.02</td>
<td>0.51</td>
</tr>
<tr>
<td>XRN2</td>
<td>20p11.22/21266977</td>
<td>A/C</td>
<td>0.82</td>
<td>0.88 (0.79–0.99)</td>
<td>1.00</td>
<td>0.03</td>
<td>0.93 (0.84–0.99)</td>
<td>0.09</td>
<td>0.13</td>
</tr>
</tbody>
</table>

Abbreviation: EAF, effect allele frequency.

aLocation based on NCBI Human Genome Build 36.3, Hg19.

bEffect/reference alleles.
cEffect allele frequency in controls.

dAdjusted for age.
eImputation R-square.

The most significant association was observed in intronic SNP rs7834784 in EIF2C2 with OR$_{per-allele}$ as 1.15 (95% CI, 1.02–1.29; $P_{meta} = 0.021$). Study specific estimates of both studies were generally similar. However, these nominally significant associations were not significant when accounting for multiple comparisons. The results of all the SNPs evaluated were presented in Supplementary Table S3.

Results

Of the 247 SNPs, 8 SNPs (DDX20 rs3754025, EIF2C2 rs7834784 and PIWIL1 rs10584087, DICER1 rs12432281, SMAD6 rs7170982, and XRN2 rs10485627) were associated with breast cancer risk ($P_{meta} < 0.050$, Table 1). The most significant association was observed in intronic SNP rs7834784 in EIF2C2 with OR$_{per-allele}$ as 1.15 (95% CI, 1.02–1.29; $P_{meta} = 0.021$). Study specific estimates of both studies were generally similar. However, these nominally significant associations were not significant when accounting for multiple comparisons. The results of all the SNPs evaluated were presented in Supplementary Table S3.

Discussion

In this study, SNPs in miRNA biogenesis pathway genes were not associated with breast cancer risk. We could not exclude the possibility that the lack of association could come from the differences in subject characteristics, the interactions of environmental modifiers, and other uncontrolled bias between both studies. We also could not replicate the SNPs shown in previous report (3) although highly correlated proxies were included aside from SNPs in DDX20. Considering the sample size of the previous report, it could be a chance finding and at least need to be further investigated in other populations. The strengths of this study are its large sample size and comprehensive search of genes of interests and the high coverage of known SNPs. With the current sample size, for a SNP with MAF as 0.26 (average value of all tested SNPs), the minimum log-additive OR that we can detect at 99% power is 1.22, considering the Bonferroni-corrected significance level ($P = 1E-04$). Future genomic scan including several kinds of structural variations, copy number variants, new variants identified by high-resolution sequencing with larger sample size, as well as subtype specific...
analysis, could elucidate further information on the potential association.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: H. Sung, S.K. Park, D. Kang
Development of methodology: H. Sung, D. Kang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Sung, K.-Y. Yoo, D.-Y. Noh, W. Zheng

Writing, review, and/or revision of the manuscript: H. Sung, B. Zhang, Y.-J. Choi, S.K. Park, D.-Y. Noh, D. Kang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.-Y. Noh, W. Zheng

Study supervision: D. Kang, W. Zheng

Grant Support
This research was supported by BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347).

Received May 18, 2012; revised June 6, 2012; accepted June 13, 2012; published OnlineFirst June 19, 2012.

References
Common Genetic Variants in the MicroRNA Biogenesis Pathway Are not Associated with Breast Cancer Risk in Asian Women

Hyuna Sung, Ben Zhang, Ji-Yeob Choi, et al.

Cancer Epidemiol Biomarkers Prev. Published OnlineFirst June 19, 2012.